Elcelyx Therapeutics snaps up $40 mln Series E

By Iris Dorbian — 4 months ago

San Diego-based Elcelyx Therapeutics, a developer of drugs for metabolic disorders, has secured $40 million in Series E funding. Sailing Capital led the round with participation from other investors that included Morgenthaler Ventures, Kleiner Perkins Caufield & Byers, Technology Partners and GSM Fund LLC. In addition to the funding, Elcelyx has appointed Liang Tsui, a managing director and partner of Sailing Capital, to its board of directors.

Continue

Kinetic Technologies buys VC-backed Akros Silicon

By Iris Dorbian — 4 months ago

Kinetic Technologies has acquired Silicon Valley-based Akros Silicon, a provider of energy management ICs. No financial terms were disclosed. Akros Silicon’s backers included Technology Partners, U.S. Venture Partners, Levensohn Venture Partners and SPM Capital.

Continue

Redmile Group leads Series B round for Scioderm

By Iris Dorbian — 1 year ago

Scioderm, a Durham, NC-based pharmaceutical firm, has closed $20 million in Series B funding. Redmile Group led the round with participation from other investors that included Morganthaler Ventures and Technology Partners. J.P. Morgan Securities was the placement agent on the transaction.

Continue

Solar cell maker Solexel bags $31 mln

By Iris Dorbian — 2 years ago

Solexel has closed $31 million in financing. The investors included GAF, Kleiner Perkins Caufield & Byers, Technology Partners, DAG Ventures, Northgate Capital, GSV Capital Corp. Gentry Venture Partners and Jasper Ridge Partners. Based in Milpitas, Calif., Solexel is a solar cell and module maker.

Continue

H.I.G. BioVentures leads Series C round for ForSight VISION5

By Iris Dorbian — 2 years ago

ForSight VISION5 has closed $15 million in Series C financing. H.I.G. BioVentures led the round with participation from previous backers Morgenthaler Ventures, Versant Ventures, Technology Partners and Delphi Ventures. Concurrent with the funding, Aaron Davidson of H.I.G. BioVentures has been added to ForSight VISION5’s board of directors. Based in Menlo Park, Calif., ForSight VISION5 focuses on developing products that replace eye drops.

Continue

Akros Silicon Secures Financing and New Investor

By Angela Sormani — 3 years ago

Akros Silicon, a supplier of intelligent energy management ICs, has secured additional financing bringing total funding in the company to $11 million. Technology Partners led the round as well as existing investors USVP, Levensohn Venture Partners and SPM Capital. Akros has also welcomed Marc van den Berg from Technology Partners to its board of directors.

Continue

Benvenue Medical Appoints Two to Board

By Angela Sormani — 4 years ago

Benvenue Medical, a developer of minimally invasive solutions for spine repair, has appointed two new members to its board of directors. Thomas M. Prescott, president and CEO of Align Technology and Thomas C. Wilder, president and CEO of Sequent Medical are both experienced in bringing medical technologies to the global marketplace. Investors in Benvenue Medical […]

Continue

Solar Startup Solexel Raises $25M, According To Filing

By Mark Boslet — 4 years ago

Solar startup Solexel has raised $25 million in new capital, according to a filing with the Securities and Exchange Commission. No other details about the funding were available. The company received Series A financing in 2007 and a Series B round in 2008. Its board includes representatives of Kleiner Perkins Caufield & Byers, Technology Partners […]

Continue

Medley Health Raises $20M Series A to Help Doctors Manage Practices

By Lawrence Aragon — 4 years ago

Medley Health, which provides physician practice management services, announced Wednesday that it had raised $20 million in Series A financing from Cardinal Partners, Technology Partners and Vivo Ventures. The Dublin, Calif.-based company says it will use the capital to expand its physician partnerships, invest in its practice management services and boost staffing. “As a physician, I understand firsthand […]

Continue

Transcend Medical Sews Up $51M Series B

5 years ago

Transcend Medical Inc., a Menlo Park, Calif.-based ophthalmic device company, has closed a second tranche of its Series B round, bringing the total to an eye-popping $51 million. Investors include Investor Growth Capital, Canaan Partners, Finistere Ventures, HLM Venture Partners, Kaiser Permanente Ventures, Latterell Venture Partners, Morgenthaler Ventures, Split Rock Partners and Technology Partners. The company says it will use the funds to develop additional infrastructure and resources for a U.S. study of its micro-stent technology. The company is focused on minimally invasive glaucoma therapies.

Continue

Revance Therapeutics Closes on $45M

5 years ago

Revance Therapeutics Inc., a drug developer focused on dermatology and aesthetic medicine, has raised $45 million in new capital from Essex Woodlands Health Ventures, NovaQuest Capital, CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital Corporation. Jonathan Tunnicliffe, a partner at NovaQuest, will join the Revance board as a result of the round. Revance closed a $25.62 million in Series D funding in late 2009.

Continue

Benvenue Medical Wraps Up $35.5M in Series C

5 years ago

Benvenue Medical Inc., a Mountain View, Calif.-based developer of minimally invasive solutions for spine repair, has closed a $35.5 million Series C round. Domain Associates and Technology Partners co-led the round, which included support from existing shareholders Versant Ventures and DeNovo Ventures. Nimesh Shah, principal at Domain Associates, and Roger Quy, general partner of Technology Partners, will join the board as a result of the round.

Continue

VCs Put More Money to Work in Fewer Deals in Q1: Report

By Mark Boslet — 5 years ago

Investment dollars inched higher in the first quarter as venture capitalists favored later stage deals and returned with interest to cleantech and life science, according to the MoneyTree Report by PricewaterhouseCoopers LLP and the National Venture Capital Association (NVCA), based on data from Thomson Reuters.

U.S. venture firms put $5.9 billion to work in the first three months of 2011, a 13% rise from Q1 2010 and a 5% increase from the fourth quarter, according to the report.

Continue